AZD1775

Ligand id: 7702

Name: AZD1775

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 100.96
Molecular weight 500.26
XLogP 2.93
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Several Phase II clinical trials of AZD1775 are underway for a variety of oncological indications including, ovarian, peritoneal or fallopian tube cancers, previously treated non-small-cell lung cancer, childhood refractory solid tumours and recurrent or metastatic head and neck cancer. All of these trials are testing AZD1775 in combination with other chemotherapeutic agents. Click here to link to ClinicalTrials.gov's full listing of AZD1775 Phase II trials. Phase 1 clinical trial NCT02617277 has begun, to evaluate combination of AZD1775 with the immune checkpoint inhibitor durvalumab (anti-PD-L1 mAb) in patients with selected advanced solid tumours.
Mechanism Of Action and Pharmacodynamic Effects
In vitro, AZD1775 inhibits Wee1 activity, inducing DNA damage and effecting G2 checkpoint escape.